Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
97 hedge funds and large institutions have $500M invested in Avadel Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 30 increasing their positions, 31 reducing their positions, and 9 closing their positions.
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
11% more funds holding
Funds holding: 87 → 97 (+10)
3% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 31
11% less call options, than puts
Call options by funds: $907K | Put options by funds: $1.01M
20% less capital invested
Capital invested by funds: $623M → $500M (-$122M)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$17.4M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$16.6M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$13.4M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.51M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$8.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$12.8M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$8.63M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$6.66M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$5.67M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$4.96M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCM
101
Hodges Capital Management
Dallas,
Texas
| – | -$254K | -12,000 | Closed |
|
|
SSG
102
Summit Securities Group
New York
| – | -$13K | -600 | Closed |
|
|
BRWM
103
B. Riley Wealth Management
Memphis,
Tennessee
| – | -$7K | -350 | Closed |
|
104
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$3K | -147 | Closed |
|
|
FHA
105
First Horizon Advisors
Memphis,
Tennessee
| – | +$330 | +15 | New |
|
AVDL Hedge Fund Activity: Q3 2015 in Review
97 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2015, worth a combined $500M — down 20% from $623M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AVDL positions and 9 closed out — a net gain of 11 holders — while 30 added to existing stakes and 31 trimmed.
The largest buyer was AllianceBernstein, opening a new position worth an estimated $17.4M. The largest seller was Broadfin Capital, cutting an estimated $12.8M.
- 97 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2015, up from 87 in Q2 2015.
- Funds reported $500M of Avadel Pharmaceuticals stock for Q3 2015, down 20% quarter-over-quarter.
- 20 funds opened new Avadel Pharmaceuticals positions in Q3 2015 and 9 closed out, a net change of +11 holders.
- The largest Avadel Pharmaceuticals buyer in Q3 2015 was AllianceBernstein, an estimated $17.4M added.
- The largest Avadel Pharmaceuticals seller in Q3 2015 was Broadfin Capital, an estimated $12.8M sold.
Based on aggregated 13F filings for Q3 2015.